Literature DB >> 24911319

Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice.

Rachel L Poole1, David A Connor1, Thomas J Gould1.   

Abstract

Withdrawal from chronic nicotine is associated with cognitive deficits. Therapies that ameliorate cognitive deficits during withdrawal aid in preventing relapse during quit attempts. Withdrawal-induced deficits in contextual learning are associated with nicotinic acetylcholine receptor upregulation. The aim of the present study was to determine if the acetylcholinesterase inhibitor donepezil has the ability to reverse nicotine withdrawal-induced deficits in contextual learning. Results demonstrated that low doses of donepezil, which do not enhance contextual learning or alter locomotor activity/anxiety-related behavior, can reverse nicotine withdrawal-induced deficits in contextual learning. Thus, donepezil may have therapeutic value for ameliorating cognitive deficits associated with nicotine withdrawal and for preventing relapse. PsycINFO Database Record (c) 2014 APA, all rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24911319      PMCID： PMC4172524          DOI： 10.1037/bne0000003

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN： 0735-7044            Impact factor:   1.912


  48 in total

1.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 2.  Effects of abstinence from tobacco: valid symptoms and time course.

Authors:  John R Hughes
Journal:  Nicotine Tob Res       Date:  2007-03       Impact factor: 4.244

3.  Long-term effects of chronic nicotine exposure on brain nicotinic receptors.

Authors:  Morgane Besson; Sylvie Granon; Monica Mameli-Engvall; Isabelle Cloëz-Tayarani; Nicolas Maubourguet; Anne Cormier; Pierre Cazala; Vincent David; Jean-Pierre Changeux; Philippe Faure
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

4.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

Review 5.  Update on pharmacologic options for smoking cessation treatment.

Authors:  Mitchell Nides
Journal:  Am J Med       Date:  2008-04       Impact factor: 4.965

6.  Nicotine withdrawal disrupts both foreground and background contextual fear conditioning but not pre-pulse inhibition of the acoustic startle response in C57BL/6 mice.

Authors:  Jessica M André; Danielle Gulick; George S Portugal; Thomas J Gould
Journal:  Behav Brain Res       Date:  2008-02-20       Impact factor: 3.332

7.  Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study.

Authors:  Marcelo Mamede; Koichi Ishizu; Masashi Ueda; Takahiro Mukai; Yasuhiko Iida; Hidekazu Kawashima; Hidenao Fukuyama; Kaori Togashi; Hideo Saji
Journal:  J Nucl Med       Date:  2007-10-17       Impact factor: 10.057

Review 8.  Review. Neurobiology of nicotine dependence.

Authors:  Athina Markou
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

9.  Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning.

Authors:  George S Portugal; Thomas J Gould
Journal:  Pharmacol Biochem Behav       Date:  2007-08-23       Impact factor: 3.533

Review 10.  It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood.

Authors:  Marina R Picciotto; Nii A Addy; Yann S Mineur; Darlene H Brunzell
Journal:  Prog Neurobiol       Date:  2007-12-27       Impact factor: 11.685
View more
  7 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

Review 2.  Negative affective states and cognitive impairments in nicotine dependence.

Authors:  F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-06-06       Impact factor: 8.989

Review 3.  Cholinergic regulation of fear learning and extinction.

Authors:  Marlene A Wilson; Jim R Fadel
Journal:  J Neurosci Res       Date:  2016-10-05       Impact factor: 4.164

Review 4.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

Review 5.  Rodent models for nicotine withdrawal.

Authors:  Ranjithkumar Chellian; Azin Behnood-Rod; Dawn M Bruijnzeel; Ryann Wilson; Vijayapandi Pandy; Adriaan W Bruijnzeel
Journal:  J Psychopharmacol       Date:  2021-04-22       Impact factor: 4.562

6.  Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.

Authors:  R L Ashare; B A Kimmey; L E Rupprecht; M E Bowers; M R Hayes; H D Schmidt
Journal:  Transl Psychiatry       Date:  2016-01-19       Impact factor: 6.222

Review 7.  The long-term cognitive consequences of adolescent exposure to recreational drugs of abuse.

Authors:  Sean M Mooney-Leber; Thomas J Gould
Journal:  Learn Mem       Date:  2018-08-16       Impact factor: 2.460
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.